Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures: an add-on, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Clinical Trial

NCT01527513 is registered in ClinicalTrials.gov with Bial - Portela C S.A. as lead sponsor.

NCT NCT01527513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01527513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures: an add-on, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Clinical Trial
Lead sponsor
Bial - Portela C S.A.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2010
Completion date
May 31, 2013
Enrollment
123 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

partial epilepsy